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Objectives The purpose of this study was to evaluate the technical feasability, safety, and 1-year efficacy of the endovascu-
lar treatment of atherosclerotic common femoral artery (CFA) obstructions.
Background Atherosclerotic CFA obstruction is a known cause of symptomatic peripheral arterial disease. Although surgical
endarterectomy is considered the therapy of choice for this condition, little is known about the percutaneous
options.
Methods Using a prospectively maintained single-center database, we retrospectively analyzed the outcomes of 360 con-
secutive percutaneous interventions of the CFA for atherosclerotic disease and assessed procedural success,
in-hospital complications, and 1-year patency and target lesion revascularization rates.
Results Ninety-seven procedures (26.9%) were isolated CFA interventions, whereas 157 (43.6%) and 152 (42.2%)
also involved inflow and outflow vessels, respectively. Bifurcation lesions were present in 140 cases
(38.9%), and concomitant treatment of the profunda femoral artery was performed on 93 occasions
(25.8%). Chronic total CFA occlusions were recanalized in 60 cases (16.7%). Balloon angioplasty was per-
formed as the primary intervention in virtually all cases (98.6%), whereas stenting was needed for subopti-
mal angioplasty results in 133 procedures (36.9%). Failures—defined as a final angiographic result with a
30% residual stenosis—were observed on 26 occasions (7.2%). In-hospital major (i.e., requiring surgery)
and minor (i.e., treated percutaneously or conservatively) complications occurred in 5 (1.4%) and 18 (5.0%)
procedures, respectively. One-year follow-up data were available for 281 patients (87.5%). Restenosis
50% by duplex scanning and target lesion revascularization were observed in 74 of 268 (27.6%) and
64 of 322 (19.9%) procedures, respectively.
Conclusions This large series suggests that the percutaneous approach may be a valid alternative to surgery for CFA athero-
sclerotic obstructions. (J Am Coll Cardiol 2011;58:792–8) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.070Common femoral artery (CFA) disease may cause claudi-
cation and critical limb ischemia and is usually part of a
broader atherosclerotic involvement including the aortoiliac
or femoropopliteal territories (1). Although percutaneous
treatment has been accepted as the preferred initial revas-
cularization strategy for the majority of atherosclerotic
obstructions in the lower limb, CFA disease remains a
mainly surgical domain because it is easily accessible and
From the *Angiology Division, Heart Center, Bad Krozingen, Germany; †Cardiology
Division, University Hospital, Geneva, Switzerland; and the ‡Angiology Division,
Kantonspital, Chur, Switzerland. The authors have reported that they have no
relationships relevant to the contents of this paper to disclose.Manuscript received June 22, 2010; revised manuscript received December 27,
2010, accepted January 3, 2011.endarterectomy is associated with favorable long-term out-
comes (2,3). In the last few years, the improvements in
endovascular equipment and the technical skills of operators
have led to an increasing number of percutaneous CFA
interventions. Herewith, we report a single tertiary center
experience of consecutive percutaneous CFA interventions
over an 11-year period.
See page 799
Methods
From a prospectively maintained database, we retrospec-
tively selected all consecutive patients who underwent a
percutaneous CFA intervention between September 1996
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August 16, 2011:792–8 Endovascular Treatment of Common Femoral Artery Diseaseand December 2007 at the Angiology Division of the Heart
Center in Bad Krozingen, Germany. Patients with diseases
of nonatherosclerotic nature or complicating another endo-
vascular procedure were excluded from the analysis (Fig. 1).
Concomitant inflow and outflow lesions requiring revascu-
larization were described as suprainguinal (i.e., iliac) or
infrainguinal (i.e., femoropopliteal, below the knee or af-
fecting a bypass) territories. Bifurcation lesions of the CFA
were classified according to the Medina classification. This
classification was developed for the coronary arteries, and it
is now applied for the first time also in the femoral
bifurcation (4) (Fig. 2).
Figure 1 Patients/Lesion Flow Chart
The flow chart shows the included/excluded patients and interventions, common femo
nonatherosclerotic disease (e.g., thromboembolic occlusions, iatrogenic dissections, l
stenoses (i.e., 70%), and patients in whom the CFA was treated following a bleeding
Fem-pop  femoropopliteal; PFA  profunda femoral artery; PTA  percutaneous tranThe aim of this analysis was to
establish the feasibility (defined as
number of successful procedures/
number of attempts), technical
success rate (defined as a final
angiographic residual stenosis
30%), safety (i.e., in-hospital
major and minor complications),
and medium-term outcomes of
the endovascular CFA approach.
Clinical follow-up, as well as
duplex ultrasound (US), were per-
Abbreviations
and Acronyms
ABI  ankle-brachial index
CFA  common femoral
artery
CI  confidence interval
OR  odds ratio
TLR  target lesion
revascularization
US  ultrasound
ery (CFA) lesion characteristics, and interventions that were performed. Patients with
associated with a vascular closure device [VCD]), hemodynamic nonsignificant CFA
lication after angiography were excluded from the analysis. angio  angiography;
al angioplasty; SFA  superficial femoral artery; TEA  thromboendarterectomy.ral art
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Binary restenosis (50%) was defined as a stenotic peak
velocity ratio (PVR) 2.4 (PVR  stenotic peak systolic
elocity [PSV]/pre-stenotic PSV). Restenoses 50% observed
eyond 18 months were considered disease progression not related
o the procedure and were excluded from the outcome analysis.
Percutaneous CFA treatment was considered efficacious
n the absence of restenosis (50%) and target lesion
evascularization (TLR)—either percutaneous or surgical—at
ollow-up. Because the majority of the CFA procedures
ere associated with an additional iliac or femoropopliteal
rocedure, the ankle-brachial index (ABI) and claudication
lass were not considered valuable parameters to appreciate
he hemodynamic impact of CFA revascularization and thus
ere not reported in the detailed patients’ analysis.
tatistical analysis. Continuous variables were expressed
s mean  SD. Categorical data were presented as numbers
nd percentages, and comparisons among the groups were
ade with the chi-square test. p  0.05 was considered
tatistically significant. Univariate analysis of clinical and
rocedural predictors of adverse events (i.e., procedural
ailure, periprocedural and in-hospital complications, reste-
osis, and 1-year TLR) was performed for approximately 20
arameters. Factors showing p  0.1 were then included in
logistic regression model, and the odds ratios (ORs) and
5% confidence intervals (CIs) were computed.
esults
uring 11 years, 466 consecutive patients underwent 516
ercutaneous CFA interventions. A total of 145 patients
156 lesions) were excluded from the analysis because the
rocedure was performed for nonatherosclerotic disease or
Figure 2 Common Femoral Bifurcation Schematics
The schematics were adapted to the coronary Medina classification (4). Bifur-
cation lesions of the CFA were classified according to the Medina classifica-
tion, a classification developed for coronary arteries that was applied for the
first time to femoral bifurcation. CFA  first number; SFA  second number;
and PFA  third number. EIA  external iliac artery; 1  presence of signifi-
cant stenosis; 0  absence of significant stenosis; other abbreviations as in
Figure 1.o treat an endovascular access complication (Fig. 1). Of the Temaining 321 patients with a significant (70%) CFA
esion, 39 (12.1%) presented with a bilateral CFA stenosis,
or a total of 360 procedures. The baseline patient charac-
Baseline Characteristics of Patients (N  321)Table 1 Baseline Characteristics of Patients (N  321)
Age, yrs 67.6 9.1
Male 260 (81)
Coronary artery disease 185 (57.6)
Lung disease 51 (15.9)
Chronic kidney failure 85 (26.5)
Diabetes mellitus 124 (38.6)
Insulin-treated 42 (13.1)
Arterial hypertension 259 (80.7)
Smoking
Yes 123 (38.3)
Former 99 (30.8)
Hyperlipidemia 251 (78.2)
Claudication according to Leriche-Fontaine classification
IIa 42 (13.1)
IIb 208 (64.8)
III 18 (5.6)
IV 53 (16.5)
Values are mean  SD or n (%).
Lesion Characteristics,Procedural De ail , and EquipmentTable 2 Lesion Characteristics,Procedural Details, and Equipment
Post-TEA 50 (14)
Pre-procedural degree of stenosis 81 12
Post-procedural degree of stenosis 26 11
Chronic total occlusion 60 (17)
Bifurcation lesion 140 (39)
Medina
1-0-0 20 (14)
1-0-1 26 (19)
1-1-0 27 (19)
1-1-1 67 (48)
Associated chronic SFA occlusion 79 (22)
Associated significant PFA lesion 93 (26)
Isolated CFA intervention 97 (27)
CFA  1 other vascular intervention 263 (73)
CFA  suprainguinal intervention 111 (31)
CFA  infrainguinal intervention 106 (29)
CFA  supra and infrainguinal
intervention
46 (13)
Procedures (n  360)
Balloons 355 (98.6)
Balloon diameter, mm* 6.55 0.8
Stent procedures 133 (36.9); 144 CFA stents
Stent diameter, mm 7.6 0.91
Stent length, mm 45.4 26.3
Additional stent procedures
(SFA-PFA)
31
(15 SFA and 20 PFA stents [35 total])
Atherectomy 25 (6.9)
Values are n (%) or mean  SD. *The choice of the balloon size was always performed by visual
estimation (i.e., no quantitative vessel analysis). The balloons were always selected as short as
possible. The balloon dilation pressure was nominal according to the manufacturer recommenda-
tions, with an inflation time of 1 to 2 min.CFA common femoral artery; PFA profunda femoral artery; SFA superficial femoral artery;
EA  thromboendarterectomy.
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August 16, 2011:792–8 Endovascular Treatment of Common Femoral Artery Diseaseteristics, as well as the lesion and procedural parameters
and techniques, are reported in Tables 1 and 2. Balloon
angioplasty was performed as the primary intervention in
virtually all patients (98.6%), and stenting was used as
bailout indication, at the operators’ discretion, for flow-
Clinical and Procedural OutcomesTable 3 Clinical and Procedural Outcomes
Procedural success (i.e., 30% stenosis) 334/360 (92.8)
Peri-procedural complications 23/360 (6.4)
Contralateral access site complications 6/360 (1.7)
Distal embolization 6/360 (1.7)
Thrombotic vascular events 6/360 (1.7)
Minor complications (i.e., AV fistula, non–flow-
limiting dissections)
5/360 (1.4)
Restenosis (50%) rate at 10.35.4 months 74/268 (27.6)
TLR 64/322 (19.9)
Percutaneous* 48/322 (14.9)
Surgical† 16/322 (5.0)
Late restenosis (i.e., 18 months) 36/174 (20.7)
Late TLR (i.e., 18 months) 34/174 (19.5)
Percutaneous 24/174 (13.8)
Surgical 10/174 (5.7)
Pre-procedural ABI 0.448 0.208
Post-procedural ABI 0.704 0.227
1-yr ABI‡ 0.676 0.225
In-hospital death 4 (1.2)
1-yr death 29/322 (9) at 8.25.6 months
Late death (i.e., 18 months) 29/322 (9) at 53.622.7 months
In-hospital myocardial infarction 4 (1.2)
In-hospital TLR 0
In-hospital major amputation 0
In-hospital minor amputation 1 (0.3)
1-yr major amputation 1 (0.3)
1-yr minor amputation 2 (0.6)
Late amputation 2 (0.6)
*Values are n/N (%) or mean SD. Percutaneous target lesion revascularization (TLR) included 26
reangioplasties, 13 stents, 6 directional atherectomies, 2 mechanical thrombectomies, and 1 in
situ thrombolysis. †Surgical TLR included 13 endarterectomies, 2 femoropopliteal bypasses, and 1
aortobifemoral Y prosthesis. ‡Ankle-brachial index (ABI) was obtained in 242 of 360 interventions
(67.2%).
AV  arteriovenous; other abbreviations as in Table 2.
Multivariate Analysis of Clinical and Procedural Predictors of AdveTable 4 Multivariate Analysis of Clinical and Procedural Predic
Endpoint Variable
Procedural failure* IDDM
Bifurcation
Stent use
2001 vs. 2001
Peri-procedural complications IDDM and NIDDM
Chronic total occlusion
Restenosis 50%† Stent use
Bifurcation
Medina 1-0-0
TLR‡ CFA  infrainguinal intervention
Bifurcation
Medina 1-0-0
Stent use*Procedural failure defined as final angiographic result with 30% residual stenosis. †Restenosis 50%
CI  confidence interval; CTO  chronic total occlusion; IDDM  insulin-dependent diabetes; NIDDM limiting dissections or suboptimal results (i.e., 50% residual
tenosis).
Table 3 reports clinical and procedural outcomes as well
as restenosis and TLR rates at follow-up. Duplex US or
clinical follow-up controls were available for 281 of 321
patients (87.5%) and 316 of 360 procedures (87.8%) for a
mean of 10.3  5.4 months. The restenosis rate was 27.6%
(74 of 268 analyzable lesions), whereas the clinically driven
TLR rate was 19.9% (64 of 322 analyzable interventions).
Patients presenting with restenosis and those presenting
with TLR were matched. Procedural-related complications
were observed on 23 of 360 occasions (6.4%): 5 (1.4%)
required surgery and the remaining 18 (5.0%) were treated
percutaneously or conservatively.
The results of multivariate analyses addressing the pre-
dictors of adverse events are reported in Table 4. Probably
related to the operators’ experience and the improvement of
the equipment, the performance of CFA interventions in
the second period of the study (i.e., 2002 to 2007) was
independently associated with a decreased risk of procedural
failure (OR: 0.35; 95% CI: 0.15 to 0.83; p  0.013). The
combination of a CFA intervention with another infrain-
guinal procedure was associated with an increased risk of
1-year TLR (OR: 1.97; 95% CI: 1.12 to 3.44; p  0.015),
whereas no significant outcome differences were observed
for de novo lesions compared with post-endarterectomy
lesions (Table 5). Procedures involving the CFA bifurcation
were further associated with an increase of risk of procedural
failure (OR: 2.71; 95% CI: 1.19 to 6.15; p  0.013) and a
trend toward more restenosis and TLR at 1 year. The use of
stents was identified as the only independent protective
factor against procedural failure (OR: 0.20; 95% CI: 0.06 to
0.69; p  0.005), 1-year restenosis (OR: 0.53; 95% CI 0.29
to 0.97; p  0.046), and TLR (OR: 0.49; 95% CI: 0.26 to
0.91; p  0.021), whereas the use of atherectomy devices
was associated with only a trend toward significant TLR
reduction (Table 5).
vents for CFA Interventionsf Adverse Events for CFA Interventions
Present vs. Absent OR 95% CI p Value
0 vs. 9.0 0.11 0.006–1.90 0.040
11.4 vs. 4.5 2.71 1.19–6.15 0.013
2.2 vs. 10.1 0.20 0.06–0.69 0.005
5.5 vs. 14.1 0.35 0.15–0.83 0.013
2.8 vs. 8.6 0.31 0.10–0.93 0.028
11.7 vs. 5.3 2.34 0.92–5.97 0.067
20.0 vs. 31.8 0.53 0.29–0.97 0.046
34.3 vs. 24.7 1.68 0.97–2.91 0.066
8.3 vs. 37.9 0.15 0.02–1.20 0.043
25.9 vs. 15 1.97 1.12–3.44 0.015
24 vs. 16.8 1.56 0.89–2.72 0.115
5.3 vs. 27.3 0.15 0.02–1.15 0.038
13.1 vs. 23.6 0.49 0.26–0.91 0.021rse Etors o
%at 12 months’ follow-up (duplex or angiographic evaluation). ‡TLR at 12 months’ follow-up.
non–insulin-dependent diabetes; OR  odds ratio; other abbreviations as in Table 2.
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patency (Fig. 3A) and freedom from TLR (Fig. 3B) over
time.
Discussion
This series of consecutive endovascular procedures involving
severe atherosclerotic stenosis of the CFA—to our knowl-
edge the largest published so far—shows that CFA percu-
taneous interventions are associated with high success
(92.8%) and low complication rates (1.4% of major and
5.0% of minor complications). The 1-year binary restenosis
rate of 27.6% and clinically driven TLR rate of 19.9% are
lower than the ones commonly encountered in the superfi-
cial femoral artery (5).
Technical aspects for CFA interventions: angioplasty
versus stenting. Stenting in the iliac and femoropopliteal
regions (especially for long lesions) is associated with a
better patency rate compared with that of balloon angio-
plasty alone (1,5); however, stent fracture or crushing
remains independent predictors of poor outcomes (6). In
our series, stenting in the CFA location was used only in the
case of flow-limiting dissection or unsatisfactory results.
Interestingly, our analysis showed that stenting, even in the
groin region, still remained a favorable independent predic-
tor for less restenosis and TLR at 1 year, without an
increased incidence of fracture on duplex US examination.
The technical procedural success with angioplasty alone,
using balloons well matched to the original CFA vessel
diameter, was achieved in 63.1% of the procedures. In the
remaining cases where stenting was necessary, our strategy
Multivariate Analysis of Outcomes for 4 DifferenTable 5 Multivariate Analysis of Outcomes
Isolated CFA (n  97), % CFA  Ot
Failures 7.2
Complications 4.1
Restenosis 26.0
1-yr TLR 15.9
De Novo (n  310), % P
Failures 7.7
Complications 5.5
Restenosis 29.6
1-yr TLR 20.4
Stented (n  133) % Non
Failures 2.2
Complications 7.5
Restenosis 20.0
1-yr TLR 13.1
Atherectomy (n  25), % PTA
Failures 4.0
Complications 0
Restenosis 11.8
1-yr TLR 4.8
Abbreviations as in Tables 2 and 4.was always to favor a 1-stent technique, in order to avoid too bmuch stents and struts overlap in the CFA bifurcation.
Indeed, by treating bifurcation lesions, adopting a 1-stent
technique can be recommended as the preferred bifurcation
stenting approach, because it is easier to perform and is
associated with better outcomes (7–9).
Despite the good results shown in the stent subgroup
analysis, several caveats should be considered before broadly
applying stenting for the treatment of CFA lesions. When-
ever possible, preservation of the CFA access should be
targeted to allow subsequent percutaneous coronary and
peripheral interventions, as well as surgical procedures.
Therefore, if stenting is needed, a self-expanding stent as
short as possible (e.g., 20 to 30 mm) should be chosen to
allow the placement of the femoral bypass anastomosis or
the CFA puncture—under fluoroscopic guidance—just
above or below the implanted stent. Finally, in rare cases
when no other vascular access is available, direct puncture
through the CFA stent may be carefully performed (10).
Recently, at our institution, the Silverhawk atherectomy
device (ev3 Endovascular, Inc., North Plymouth, Minne-
sota) became one of the preferred revascularization strate-
gies for CFA intervention, with the exception of severe
calcific lesions. This is because with the Silverhawk or
similar atherectomy devices, it is possible to obtain a good
angiographic result, avoiding balloon-induced dissections,
thus finally minimizing the need for stent implantation (11).
owever, this approach was mainly used in the last 2
ears of the series, only once operators’ experience with
he device became sufficient, allowing the safe and
fficacious treatment also of complex CFA lesions (i.e.,
ient SubgroupsDifferent Patient Subgroups
ssel PTA (n  263), % OR 95% CI p Value
7.2 1.00 0.40–2.45 1.000
7.2 0.55 0.18–1.67 0.340
28.2 0.89 0.48–1.64 0.760
21.0 0.71 0.37–1.36 0.340
A (n  50), %
4.0 0.49 0.11–2.17 0.550
12.0 2.35 0.88–6.28 0.110
16.7 0.47 0.20–1.12 0.090
14.9 0.68 0.29–1.60 0.430
d (n  227), %
10.1 0.20 0.06–0.69 0.005
5.7 1.34 0.57–3.14 0.510
31.8 0.53 0.29–0.97 0.046
23.6 0.49 0.26–0.91 0.021
nt (n  335), %
7.5 0.51 0.07–3.98 1.000
6.9 0.26 0.01–4.42 0.380
28.7 0.35 0.07–1.48 0.160
20.9 0.18 0.02–1.42 0.090t Patfor 4
her Ve
ost-TE
stente
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(OR: 0.18; 95% CI: 0.02 to 1.42; p  0.090). The lack of
tatistical significance, despite the impressive OR, is
ikely due to the limited sample size of patients treated
ith this technology (n  25).
linical implications: endovascular versus surgical
pproach for CFA lesions. Surgery is considered the gold
tandard treatment for CFA lesions. It may be associated
Figure 3 Cumulative Survival
Kaplan-Meier curve showing the cumulative survival rate without (A) restenosis
and (B) target lesion revascularization (TLR).ith a technical success rate close to 100% and a 1-year trimary patency rate approaching 93%. Long-term out-
omes after surgical endarterectomy are also favorable, with
umulative patency rates—including primary, primary as-
isted, and secondary patency—up to 90% at 5 years (2,3).
owever, the morbidity associated with the surgery is not
egligible (3,12). Accordingly, major hematoma, wound
nfection, nerve damage with persistent sensory distur-
ances, and the need for surgical revision may occur in up to
% of cases (12), and the incidence of minor complications
uch as seromas and hematomas may be as high as 20% (3).
The Transatlantic Inter-Society Consensus (TASC) II
uidelines, published in 2007, recommend a surgical ap-
roach for CFA stenosis, and no alternative treatment is
entioned in this document, fostering the assumption that
urgery is the only available approach for CFA lesions (1).
owever, it should be stressed that data for surgical CFA
ndarterectomies are rare. Indeed, the largest series pub-
ished so far included 101 patients, with a complication rate
f 22.6% (1% mortality, 3.6% complications requiring a
econd operation, and 18% minor complications) (3).
Concerning the percutaneous approaches to atheroscle-
otic CFA lesions, data are even scarcer, with only a few
etrospective series—the largest including 27 patients—
ublished so far (7,8). However, thanks to modern endo-
ascular equipment and techniques, the successful treatment
f a growing number of TASC II D lesions is now possible
13), and this trend associated with our favorable results
uggests that CFA stenosis may reasonably be treated with
n endovascular approach first.
tudy limitations. The major limitations of the present
tudy are the retrospective nature of the analysis and the lack
f a surgical control group during the same period. Another
mportant issue is that 70.7% of the patients (227 of 321)
ad a combined revascularization procedure, thus not allow-
ng isolation of the CFA revascularization effect. For this
eason, this paper, similar to most of the published CFA
eries, does not include any clinical efficacy parameters (e.g.,
BI, claudication class) and is focused only on the technical
easibility, safety, and 1-year patency and revascularization
ates (3,7,8).
Another limitation of the present study is that because of
he constant and rapid evolution of the endovascular field in
ecent years, our results, obtained from an 11-year time
eriod, might be considered relatively out of date, especially
n Europe, where modern techniques and equipment are
eadily available. However, we believe that reporting the
atisfactory results with standard techniques serves as a
oundation for further testing of newer technology.
Finally, the follow-up CFA imaging (mainly duplex US)
as not standardized and was performed at different time
oints in nearly 75% of the patients, resulting in an
nalyzable restenosis rate of 268 of 360 CFA lesions.
owever, our standard practice is to conduct clinical
ollow-up examinations and determine ABI in the first year
fter the procedure and only mandate duplex US if symp-
oms have recurred. With this routine follow-up program,
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Endovascular Treatment of Common Femoral Artery Disease August 16, 2011:792–8we have obtained sufficient data concerning restenosis and
most importantly concerning clinically driven TLR for the
majority of the patients (281 of 321 [87.5%]), and this for
the most important period concerning restenosis occurrence
(i.e., from the sixth to 18th months after the intervention).
Conclusions
This retrospective analysis of 360 consecutive CFA inter-
ventions performed in 321 patients showed that the endo-
vascular approach with balloon angioplasty and provisional
stenting is associated with a high success rate, low rate of
in-hospital complications, and acceptable restenosis rate at
medium-term follow-up. Our data suggest that the endo-
vascular approach of CFA, even for complex lesions, may be
a valid alternative to surgery. Randomized trials are needed
to define the optimal revascularization strategy for patients
with CFA atherosclerotic lesions.
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